Haemonetics (NYSE:HAE) Price Target Raised to $92.00

Haemonetics (NYSE:HAE) had its price target boosted by equities researchers at Citigroup from $79.00 to $92.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup’s price target would suggest a potential upside of 5.14% from the stock’s current price.

Several other research firms have also issued reports on HAE. JPMorgan Chase & Co. lifted their price target on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their target price for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Barrington Research set a $95.00 price objective on Haemonetics in a report on Friday. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, Robert W. Baird set a $96.00 price target on Haemonetics in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average target price of $90.89.

Haemonetics Price Performance

NYSE HAE traded up $2.48 on Friday, reaching $87.50. 657,064 shares of the stock traded hands, compared to its average volume of 853,812. Haemonetics has a 12 month low of $47.31 and a 12 month high of $88.58. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 43.32, a P/E/G ratio of 1.69 and a beta of 0.52. The firm’s fifty day simple moving average is $76.59 and its 200 day simple moving average is $66.37. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.10 EPS. As a group, research analysts predict that Haemonetics will post 5.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new position in Haemonetics in the 4th quarter worth $26,000. Leonteq Securities AG bought a new stake in Haemonetics during the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its holdings in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $34,000. Finally, Bayforest Capital Ltd acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $40,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Haemonetics reported fiscal Q1 2027 adjusted EPS of $1.14, above the $1.07–$1.08 consensus range, while revenue of $339.4 million topped estimates of $327.9 million and increased 5.5% year over year. Zacks earnings report
• Positive Sentiment: Management raised its outlook. The company now forecasts reported fiscal 2027 revenue growth of approximately 5% to 8%, supported by strength in the first quarter. The improved outlook gives investors greater confidence in near-term sales momentum. Seeking Alpha guidance report
• Positive Sentiment: BTIG Research raised its price target to $96 from $84 and maintained a Buy rating. The new target implies additional upside from current levels, reinforcing the bullish view following the earnings release. BTIG price target report
• Neutral Sentiment: JPMorgan raised its target to $86 from $62 but kept a Neutral rating. The revised target is close to the current share price, suggesting the firm views the stock as fairly valued despite the stronger results. Benzinga analyst report
• Negative Sentiment: The earnings beat initially produced a muted market reaction. Reports noted premarket weakness, potentially reflecting profit-taking and valuation concerns after the stock’s strong run toward its 52-week high. Haemonetics trades at roughly 42 times earnings, leaving limited room for execution shortfalls.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.